JOINT FILING AGREEMENTJoint Filing Agreement • February 7th, 2018 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13D, dated February 7, 2018 (the “Schedule 13D”), with respect to the Shares of Rhythm Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13D. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
Lock-Up AgreementLock-Up Agreement • February 7th, 2018 • Orbimed Advisors LLC • Pharmaceutical preparations
This letter is being delivered to you in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”), between Rhythm Pharmaceuticals, Inc., a Delaware corporation, including any predecessor or successor company, as the case may be (the “Company”), and each of you as representatives of a group of Underwriters named therein (the “Underwriters”), relating to an underwritten public offering of shares of common stock (“Common Stock”), of the Company (the “Offering”).
